Here we report the prognostic impact of MYC protein levels on survival outcomes in AML-MRC patients. METHODS: Using Total Cancer Care (TCC) Moffitt Cancer Center (MCC) databases, we retrospectively identified histologically confirmed AML-MRC patients from 2011 to 2018. MYC protein expression was ...
acute myeloid leukemia (AML)epidemiologymyelodysplastic syndrome (MDS)risk factorsTo determine the incidence, risk factors, and relative survival of acute myeloid leukemia (AML) secondary to myelodysplastic syndrome (MDS) in the Surveillance, Epidemiology, and End Results (SEER) database. Retrospective ...
Median follow-up was 3.6 The AML 8A analysis showed an 8% difference in survival rate years. We cannot disprove that after a longer follow-up, a higher at the median follow-up of 6 years, the survival being 48% for percentage of patients without a donor might relapse, and that patients...
Treatment of chronic myeloid leukemia (CML) has been profoundly improved by the introduction of tyrosine kinase inhibitors (TKIs). Long-term survival with imatinib is excellent with a 8-year survival rate of ∼88%. Long-term toxicity of TKI treatment,
AML subtypes and karyotypes were well balanced between the groups. "Overall, the survival of transplanted patients was longer in patients treated with CPX-351 versus 7+3, although in the 70 to 75 subgroup this difference did not quite reach statistical significance," noted Lancet. Those with ...
Kaplan-Meier estimation was used to evaluate survival at one and two-year period in these three types of AML. Multiple Cox proportional hazards models were used to examine the interaction between baseline characteristics (Table 1) and AML type (tAML/tMDS, sAML, de novo AML) on survival. ...
Treatment of secondary acute leukemia by bone marrow transplantation from a family member or unrelated donor suitably matched for HLA has resulted in long term disease free survival for less than 30 % of patients due to a high relapse rate and significant non-relapse mortality [4,5,6]. We ...
1-5 Therapy-related secondary myeloid neoplasms account for 10% to 20% of MDS and AML cases and are characterized by complex karyotypes and frequent TP53 (OMIM 191170) alterations.1,6,7 Resistance to standard therapies and poor outcomes are common, with 5-year survival rates of less than ...
AML with 20% blasts with either antecedent hematologic malignancies, some kind of MDS [myelodysplastic syndrome]-defining cytogenetic abnormality, or multilineage dysplasia. This was approved based on a phase III clinical trial that showed an improved overall survival for the specific niche of patients...
Median remission duration and overall survival were 3 and 9 months, respectively and not different between ID and SD patients. Although the treatment-related toxicity is high, a high CR rate can be obtained in these poor-risk AML patients with the use of intensive chemotherapy in combination ...